Study Finder

Only clinical trials help to reliably ascertain how to improve efficacy, while collecting data on the impact of adverse effects. Every well-conducted study, every participating site and patient contribute to an advanced care for tumor patients.

If you are interested in participating in a study, please don’t hesitate to contact us.

ADAPTlate

Study

Breast Cancer

Recruitment

Closed

Open

INDICATION

Breast Cancer

HR+/HER2-

after completed local treatment

THERAPY

Abemaciclib

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

BERING

NIS

Colorectal Cancer

Recruitment

Open

INDICATION

Colorectal Cancer

metastasized, BRAFV600E-mutation

1st line

THERAPY

Encorafenib + Cetuximab

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

CARAT

Registry

Urogenital Tumors

Recruitment

Open

INDICATION

Urogenital Tumors

Renal Cell Carcinoma

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

CARO

NIS

Multiple Myeloma

Recruitment

Closed

Open

INDICATION

Multiple Myeloma ≥ 2nd line

THERAPY

carfilzomib + lenalidomide + dexamethasone or CAR/DEX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

CHAPLIN

NIS

Lung Cancer

Treatment

Closed

INDICATION

Lung Cancer

stage IV non-squamous NSCLC or extensive-stage SCLC

1st line

THERAPY

atezolizumab + platin-based induction chemotherapy, atezolizumab-based maintenance therapy

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

CRISP

Registry

Lung Cancer

Recruitment

Closed

Open

INDICATION

Lung Cancer

NSCLC, stage II - IV

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

FIRST-NIS

NIS

Multiple Myeloma

Treatment

Closed

INDICATION

Multiple Myeloma 1st line

THERAPY

lenalidomide (Revlimid®) + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INGE-B

Study

Breast Cancer

Treatment

Closed

INDICATION

Breast Cancer

HR-positive / HER2-negative, inoperable or metastatic

≥ 1st line

THERAPY

1st line: palbociclib + aromatase inhibitor (letrozole / anastrozole / exemestane) or fulvestrant
≥ 2nd line: palbociclib + letrozole or fulvestrant

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

MANTA

Study

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

HER2/neu-negative, metastatic or locally advanced

2nd line

THERAPY

fulvestrant + AZD2014

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

MYRIAM

Registry

Multiple Myeloma

Recruitment

Open

INDICATION

Multiple Myeloma 1st line, 2nd line. 3rd line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

NEPTUN

NIS

Lung Cancer

Follow-Up

Closed

INDICATION

Lung Cancer

NSCLC, metastatic / advanced and inoperable

1st line

THERAPY

nab-paclitaxel + carboplatin

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

OPAL

Registry

Breast Cancer

Recruitment

Open

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

POSEIDON

NIS

Multiple Myeloma

Follow-Up

Closed

INDICATION

Multiple Myeloma

advanced

3rd line

THERAPY

pomalidomide + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

PreCycle

Study

Breast Cancer

Treatment

Closed

INDICATION

Breast Cancer

HR pos / HER2 neg, metastasized / locally advanced & inoperable

1st line to max. ≤ 4th line (max. 1 CTx and/or 2 HTx)

THERAPY

Palbociclib + aromatase inhibitor or Palbociclib + Fulvestrant

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

PRO Kidney

Tablet

Urogenital Tumors

Follow-Up

Closed

INDICATION

Urogenital Tumors

advanced, metastatic

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

REFLECT

NIS

DLBCL

Follow-Up

Closed

INDICATION

DLBCL

diffuse large B-cell lymphoma (DLBCL)
untreated, CD20-positive

1st line

THERAPY

Rixathon® (rituximab biosimilar) + CHOP

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

RIBBIT

Study

Breast Cancer

Treatment

Closed

INDICATION

Breast Cancer

HR-positive / HER2-negative, with visceral metastases, postmenopausal

1st line

THERAPY

ribociclib + aromatase inhibitor vs. paclitaxel +/- bevacizumab

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

SAPHIR

Registry

Gastric Cancer Esophageal Cancer

Recruitment

Open

INDICATION

Gastric Cancer

metastatic

Esophageal Cancer

metastatic

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

TACTIC

NIS

Colorectal Cancer

Recruitment

Closed

INDICATION

Colorectal Cancer

metastatic

THERAPY

trifluridine / tipiracil (Lonsurf®)

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Recruitment

Tumor Registry Breast Cancer

Registry

Breast Cancer

Follow-Up

Closed

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

Tumor Registry Colorectal Cancer

Registry

Colorectal Cancer

Treatment

Closed

INDICATION

Colorectal Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

Tumor Registry Pancreatic Cancer

Registry

Pancreatic Cancer

Follow-Up

Closed

INDICATION

Pancreatic Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

VALIDATE

NIS

Colorectal Cancer

Recruitment

Closed

Open

INDICATION

Colorectal Cancer

metastatic, RAS wild-type

1st line

THERAPY

panitumumab + FOLFIRI or FOLFOX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment